NCI Assists in Hurricane Relief Efforts

In the wake of Hurricane Katrina, the US National Cancer Institute (NCI) is working closely with the National Institutes of Health (NIH), the Department of Health and Human Services (HHS), and other government and civilian agencies to bring relief to displaced cancer patients and others. As an immediate response, NCI has posted key federal assistance information and phone numbers on its Web site at http://www.cancer.gov/katrina with specific information in support of cancer patients.



"This disaster has touched the entire nation," said NCI Director Dr. Andrew C. von Eschenbach. "NCI is engaged in a number of opportunities, working within the framework of lead federal agencies and with civilian organizations and relief agencies, to assist cancer patients and medical professionals in the region who have been significantly affected."



Coordinating NCI efforts is Dr. Mark Clanton. "Our first and foremost concern is the safety and well-being of medical personnel and patients in the area," Dr. Clanton said. "We are marshalling all available communication and information resources to accomplish this, and are also working to help NIH address the needs of displaced researchers and others."



NCI's Cancer Information Service (CIS) is providing staff and its 1-800-4-CANCER toll-free number toward relief efforts.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap